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Purpose: We investigated whether C-reactive protein (CRP) to serum albumin ratio (CAR) could be an independent predictor of 
all-cause mortality in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). 
Materials and Methods: We retrospectively reviewed the medical records of 170 patients with AAV. We collected clinical and lab-
oratory data. We also examined AAV-related and traditional risk factors of all-cause mortality. To assess the hazard ratios of vari-
ables, we performed univariable and multivariable Cox hazard model analyses. 
Results: The mean age was 55.0 years and 53 patients (31.2%) were male among 170 patients with AAV (88 microscopic polyangi-
itis, 43 granulomatosis with polyangiitis, and 39 eosinophilic granulomatosis with polyangiitis). ANCA was detected in 129 pa-
tients (75.9%). The initial mean CRP and serum albumin were 41.1 (mg/L) and 3.6 (g/dL), and the mean CAR at diagnosis was 
14.8. The most common risk factor of mortality was hypertension (42.4%), followed by chronic kidney disease ≥stage 3 (25.9%). 
Fourteen patients (8.2%) died during the mean follow-up of 56.7 months. In both multivariable Cox hazard model analyses, CAR 
at diagnosis was identified as an independent predictor of all-cause of mortality comparable to diabetes mellitus (DM). More-
over, patients with CAR ≥10.35 and having DM exhibited a higher frequency of all-cause mortality than those without. 
Conclusion: CAR at diagnosis can be an independent predictor of all-cause mortality, comparable to DM, the conventional risk 
factor of mortality.       
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INTRODUCTION
Antineutrophil cytoplasmic antibody (ANCA)-associated vas-
culitis (AAV) is a group of systemic vasculitides encroaching 
small vessels, from capillaries to intraparenchymal arterioles 
and venules. AAV consists of three variants, such as micro-
scopic polyangiitis (MPA), granulomatosis with polyangiitis 
(GPA), and eosinophilic granulomatosis with polyangiitis 
(EGPA).1,2 Because AAV may induce damage to major organs, 
AAV can occasionally be fatal: One year-cumulative patient 
survival rates were reported to range from 82% to 95% in 
Western countries3 and up to 79.1% in Japan.4 Meanwhile, it 
was recently reported that 10-year cumulative patient survival 
rate was 92.8% in Korean patients with AAV.5 
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So far, C-reactive protein (CRP)/serum albumin ratio (CAR) 
has been introduced as an independent predictor of all-cause 
mortality in cancers, inflammatory diseases and septic condi-
tions.6-8 Since, AAV is also an inflammatory disease involving 
systemic major organs beyond vessels,1,2 one could reason-
ably speculate that CAR might be a predictor of all-cause 
mortality during follow-up. However, no study has sought to 
clarify the clinical significance of CAR in predicting all-cause 
mortality in AAV patients. Hence, in this study, we investigat-
ed whether CAR could be an independent predictor of all-
cause mortality in 170 patients with AAV. 
MATERIALS AND METHODS
Patients
We retrospectively reviewed the medical records of 170 pa-
tients with AAV based on the following inclusion criteria: 1) 
patients who were first classified as AAV from October 2000 to 
September 2017 at the Department of Internal Medicine, Yon-
sei University College of Medicine, Severance Hospital; 2) pa-
tients who fulfilled the American College of Rheumatology 
1990 criteria for the classification of GPA and EGPA and then 
reclassified by the algorithm suggested by the European Medi-
cines Agency in 2007, in which the authors added the modified 
contents of the Chapel Hill Consensus Conferences Nomen-
clature of Vasculitis proposed in 2012;1,2 3) patients who had 
well-documented medical records with which to assess both 
clinical manifestations at diagnosis and death during follow-
up and to calculate vasculitis activity score represented by Bir-
mingham vasculitis activity score (BVAS) and prognostic fac-
tors identified by five factor score (FFS, 2009) at diagnosis;9,10 
and 4) patients who had results on perinuclear (P)-ANCA and 
cytoplasmic (C)-ANCA or myeloperoxidase (MPO)-ANCA and 
proteinase 3 (PR3)-ANCA levels at diagnosis. This study was 
approved by the Institutional Review Board of Severance Hos-
pital (4-2017-0673) who waved the need for the patient written 
informed consent, as this was a retrospective study.
Clinical and laboratory data
We obtained age at diagnosis and gender as demographic 
data. We collected clinical and laboratory results at diagnosis 
as described in Table 1. Comorbidities belonging to BVAS or 
FFS (2009), such as diffuse alveolar haemorrhage and cardio-
vascular diseases, were excluded in risk factors. We also re-
viewed medications administered during follow-up. We de-
fined the follow-up duration as the period from diagnosis to 
the last visit in surviving patients, while we defined it as the 
period from diagnosis to death in deceased patients. CAR was 
calculated as CRP (mg/L) divided by serum albumin (g/dL). 
Statistical analyses
All statistical analyses were conducted using SPSS software 
Table 1. Baseline Characteristics of Patients with AAV (n=170) (Continued)
Variables Values
At diagnosis 
Demographic data 
Age at diagnosis (yr) 55.0±15.4
Male gender 53 (31.2)
AAV variants
MPA 88 (51.8)
GPA 43 (25.3)
EGPA 39 (22.9)
ANCA positivity 129 (75.9)
MPO-ANCA (or P-ANCA) 105 (61.8)
PR3-ANCA (or C-ANCA) 28 (16.5)
Both ANCAs 8 (4.7)
ANCA negative 41 (24.1)
Clinical manifestations
General 75 (44.1)
Cutaneous 40 (23.5)
Mucous membranes/eyes 12 (7.1)
Ear Nose Throat 64 (37.6)
Pulmonary 92 (54.1)
Cardiovascular 46 (27.1)
Abdominal 10 (5.9)
Renal 99 (58.2)
Nervous systems 54 (31.8)
Activity and prognostic factor
BVAS 12.8±7.0
FFS (2009) 1.2±1.0
Laboratory results 
White blood cell (/mm3) 9992.8±4678.5
Haemoglobin (g/dL) 11.5±2.3
Platelet×103 (/mm3) 324.5±139.0
Blood urea nitrogen (mg/dL) 25.1±23.2
Creatinine (mg/dL) 1.8±2.0
Protein (g/dL) 6.7±0.9
Serum albumin (g/dL) 3.6±0.8
Alkaline phosphatase (IU/L) 89.6±84.3
Aspartate aminotransferase (IU/L) 24.0±24.4
Alanine aminotransferase (IU/L) 23.5±35.3
Total bilirubin 0.7±1.4
Acute reactants 
Erythrocyte sedimentation rate (mm/hr) 59.0±37.3
C-reactive protein (mg/L) 41.1±55.4
CAR 14.8±22.5
Comorbidities except items of BVAS or FFS(2009)  
at diagnosis*
Chronic kidney disease≥stage 3 44 (25.9)
End stage renal disease 28 (16.5)
Diabetes mellitus 34 (20.0)
Hypertension 72 (42.4)
Viral hepatitis 6 (3.5)
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(version 23 for windows; IBM Corp., Armonk, NY, USA). The 
multivariable Cox hazards model was conducted to appropri-
ately obtain hazard ratios (HR). In the multivariable Cox haz-
ards model, the levels of protein, serum albumin, and CRP 
were excluded, because they are variables related to the equa-
tion for CAR. The optimal cut-off of CAR for death (10.35) was 
extrapolated by calculating the area under the receiver opera-
tor characteristic curve (sensitivity 64.3% and specificity 
67.9%). Comparison of cumulative patient survivals between 
the two groups were analysed by the Kaplan-Meier survival 
analysis. p-values less than 0.05 were considered statistically 
significant.
RESULTS
Baseline characteristics of 170 patients with AAV 
The baseline characteristics are described in Table 1. The 
mean age was 55.0 years and 53 patients (31.2%) were male. 
The mean BVAS and FFS (2009) at diagnosis were 12.8 and 1.2, 
respectively. The initial mean CRP and serum albumin levels 
were 41.1 (mg/L) and 3.6 (g/dL), respectively, and the mean 
CAR at diagnosis was 14.8. Fourteen patients (8.2%) died dur-
ing the mean follow-up of 56.7 months. 
CAR at diagnosis and all-cause mortality during the 
follow-up
In univariable Cox hazard model analysis, CAR at diagnosis 
was significantly associated with all-cause mortality in AAV 
patients [HR 1.037, 95% confidence interval (CI) 1.015–1.060], 
along with age, BVAS, FFS (2009) ≥2, haemoglobin, blood urea 
nitrogen, alkaline phosphatase, total bilirubin, erythrocyte 
sedimentation rate, chronic kidney disease (CKD) ≥stage 3 
and DM at diagnosis. However, medications showed no pre-
dictive value for mortality (Table 2). 
Since BVAS and FFS (2009) share some items, we separately 
performed multivariable analysis with either BVAS or FFS 
(2009) ≥2, along with other variables with significance in uni-
variable analysis. In multivariable Cox hazards model analysis 
with BVAS, CAR (HR 1.048) and DM (HR 6.313) were indepen-
dent predictors of all-cause mortality in AAV patients (Table 2). 
Meanwhile, in multivariable Cox hazards model analysis with 
FFS (2009) ≥2, only CAR (HR 1.039) was an independent pre-
dictor of all-cause death in AAV patients (Table 2). 
Optimal cut-off of CAR to predict all-cause mortality 
Cumulative patient survival rates according to CAR ≥10.35 
and the presence of DM are depicted in Fig. 1. In Kaplan-Mei-
er survival analysis, patients with CAR ≥10.35 exhibited a 
higher frequency of all-cause mortality than those without 
(p<0.001). Also, patients with DM also exhibited lower cumu-
lative patient survival rate that those without (p=0.012). 
DISCUSSION
In this study, we investigated whether CAR at diagnosis could 
predict all-cause mortality during the follow-up of AAV. Also, 
we demonstrated that CAR at diagnosis is an independent 
predictor of all-cause mortality comparable to DM, the con-
ventional risk factor of mortality. Also we provided an optimal 
cut-off of CAR at diagnosis to estimate the risk of all-cause 
mortality. 
How CAR at diagnosis could be an independent predictor 
of all-cause death in AAV patients could be explained as fol-
lows: CRP is closely correlated with interleukin (IL)-6. Chronic 
inflammation enhances the production of IL-6, which, in 
turn, promotes the production of CRP in the liver, leading to 
an increase in CRP level in the peripheral circulation.11 Mean-
while, IL-6 down-regulates or inhibits the production of albu-
min in the liver, resulting in a decrease in serum albumin 
concentration.12 Accordingly, inflammatory burden can affect 
CAR via two different directions (increasing CRP and decreas-
ing serum albumin), unlike CRP or serum albumin alone. 
Thus, CAR with two variables affected by inflammatory bur-
den in AAV could be a more stable and reliable index to pre-
suppose all-cause mortality, compared to CRP or serum albu-
min alone in AAV patients. 
Here we provide two hypotheses regarding the connection 
between the inflammatory burdens at diagnosis and all-cause 
mortality in AAV patients. First, a large inflammatory burdens 
at diagnosis may provoke immunosuppressive drug-refracto-
riness or cause a situation where patients should take larger 
doses of immunosuppressive drugs or have a longer period to 
Table 1. Baseline Characteristics of Patients with AAV (n=170) (Continued)
Variables Values
During follow-up
Follow-up duration (months) 56.7±54.4
Death 14 (8.2)
Medications administered 
Glucocorticoid 145 (85.8)
Cyclophosphamide 71 (42.0)
Mycophenolate mofetil 10 (5.9)
Azathioprine 46 (27.2)
Tacrolimus 10 (5.9)
Rituximab 15 (8.9)
Methotrexate 13 (7.7)
AAV, ANCA-associated vasculitis; ANCA, antineutrophil cytoplasmic anti-
body; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; 
EGPA, eosinophilic granulomatosis with polyangiitis; MPO, myeloperoxidase; 
P, perinuclear; PR3, proteinase 3; C, cytoplasmic; BVAS, Birmingham vasculi-
tis activity score; FFS, five factor score; CAR, C-reactive protein to serum al-
bumin ratio. 
Values are expressed as a mean±standard deviation or number (%). 
*Interstitial lung disease, diffuse alveolar haemorrhage, ischemic heart dis-
eases-related diseases and cerebrovascular accident are not included.
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receive them. This situation may exacerbate the risk of infec-
tion and cancer development.13 Second, a large inflammatory 
burden may reflect ready-made organ-damage at diagnosis 
and, furthermore, may result in end stage damage to various 
major organs during follow-up, such as diffuse alveolar haem-
orrhage and end stage renal disease.9 This situation may ag-
gravate the systemic complications of organ-damages by AAV, 
leading to an increase in all-cause mortality. In this study, the 
most common cause of death was serious infection in 12 pa-
tients [pneumonia (n=7), bacterial sepsis (n=3), influenza in-
fection (n=1), and biliary infection (n=1)]. Two patients died 
of AAV-related complication [diffuse alveolar haemorrhage 
(n=1) and cardiac arrest due to cardiomyopathy (n=1)]. This 
result might support to our hypotheses. 
In patients with AAV, infection, cardiovascular damage, ma-
lignancies, CKD, high BVAS, low haemoglobin, and immuno-
suppressive drugs were reported to be associated with all-Ta
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Fig. 1. A predictor of all cause-mortality in ANCA-associated vasculitis 
patients. Patients with CAR ≥10.35 and having DM exhibited a higher fre-
quency of all-cause mortality than those without in Kaplan-Meier survival 
analysis. ANCA, antineutrophil cytoplasmic antibody; CAR, C-reactive 
protein to serum albumin ratio; DM, diabetes mellitus.
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cause mortality.14 Meanwhile, age, male gender, DM, and 
hypertension are also considered as traditional risk factors of 
all-cause mortality in the general population.15 Recently, in 
Korean patients with AAV, it was reported that FFS (2009) at 
diagnosis ≥2 was associated with mortality.5 Accordingly, we 
included initial BVAS and FFS (2009) at diagnosis ≥2 in multi-
variable Cox hazard model analysis along with both AAV-re-
lated and traditional risk factors of all-cause mortality. In uni-
variable analysis, almost all the risk factors exhibited 
predictive potential for mortality, similar to a previous study.14 
However, in both multivariable Cox hazards model analyses 
with either initial BVAS or FFS (2009) at diagnosis ≥2, only 
CAR at diagnosis and DM were identified as an independent 
predictor of all-cause of mortality. Unlike the previous study 
investigating whether the initial clinical features and medica-
tions administered could predict all-cause mortality,5 this 
study evaluated the clinical implications of CAR among clini-
cal and laboratory variables, and so there might be a subtle 
difference in the results between the two studies. 
Although no predictive value for all-cause mortality was wit-
nessed in ANCA positivity (p=0.084) or hypertension (p=0.088)
in the univariable Cox hazards model analysis in this study, 
ANCA positivity is one of AAV-related risk factors for serious 
outcomes,16 and furthermore, hypertension is a well-known 
conventional risk factor for mortality in the general popula-
tion.15 Thus, to minimise the effect of two confounding factors, 
we included ANCA positivity and hypertension in the univari-
able Cox hazard model analysis. Regardless of ANCA positivity 
and hypertension, only CAR exhibited statistical significance 
among variables when applying either BVAS at diagnosis or 
FFS (2009) at diagnosis ≥2 in the model (HR 1.050, p=0.025, 
and HR 1.042, p=0.039) (Supplementary Table 1, only online). 
Our study has an advantage in that we first proved the clini-
cal significance of CAR at diagnosis in predicting all-cause of 
mortality and furthermore, provided an optimal cut-off of CAR 
at diagnosis to estimate the risk of all-cause mortality. Howev-
er, this study also has several limitations. First, as this study was 
designed as a retrospective study, we could not strictly control 
for confounding factors, including undocumented histories of 
medications, nutritional status related the level of serum albu-
min, and comorbidities. Second, as this study was conducted 
in a single centre, the number of deceased patients was too 
small to perform sub-group analysis based on the causes of 
mortality. Third, we could not use the cut-off of CAR in the 
multivariate Cox hazard model analysis to presuppose all-
cause mortality due to the small statistical power. This study 
may be a pilot study to first investigate the clinical implication 
of CAR in AAV patients. We believe that future prospective and 
multi-centric studies will validate the clinical implications of 
our results, and they will provide a clear optimal cut-off of CAR 
to predict all-cause mortality in AAV patients for use in real 
clinical settings. In conclusion, CAR at diagnosis can be an in-
dependent predictor of all-cause mortality, comparable to 
DM, the conventional risk factor of mortality. 
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